Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152352 | 0.90 | HCRTR1 (0.47) | HCRTR1HCRTR2CACNA1BCYP2C9CYP2C19 | |
| SCHEMBL6140644 | 0.89 | HCRTR1 (0.46) | HCRTR1HCRTR2CACNA1BACHEKMT2A | |
| SCHEMBL5150118 | 0.86 | HCRTR1 (0.46) | HCRTR1HCRTR2CACNA1BACHEKMT2A | |
| SCHEMBL5149596 | 0.86 | CACNA1B (0.46) | HCRTR1HCRTR2CACNA1BCYP2C9CYP2C19 | |
| SCHEMBL5156906 | 0.84 | CACNA1B (0.48) | HCRTR1HCRTR2CACNA1BACHEKMT2A | |
| SCHEMBL5155519 | 0.84 | HCRTR1 (0.49) | HCRTR1HCRTR2CACNA1BACHEKMT2A | |
| SCHEMBL6827571 | 0.84 | HCRTR1 (0.49) | HCRTR1HCRTR2CACNA1BACHEKMT2A | |
| SCHEMBL5151627 | 0.84 | EGLN1 (0.43) | HCRTR1HCRTR2CACNA1BACHEKMT2A | |
| SCHEMBL5152211 | 0.83 | ACHE (0.50) | HCRTR1HCRTR2CACNA1BACHEPOLB | |
| SCHEMBL5154974 | 0.82 | HCRTR1 (0.50) | HCRTR1HCRTR2CACNA1BACHEPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | TRPV2, RYR2, VDAC2 | HCRTR1 1608/4885HCRTR2 194/4885CACNA1B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.